We’re excited to announce that our Immunogenicity Assay Platform has received NABL accreditation, enhancing our testing capabilities for B and T cell Immunophenotyping and vaccine efficacy.
We are pleased to announce that our Immunogenicity Assay Platform, supported by BIRAC, has recently received NABL accreditation. This significant milestone enhances our capability to perform advanced testing, including Immunophenotyping of B and T cells, as well as assessing Vaccine efficacy.
